Author: admin

Following the Middle East conflict and closure of the Strait of Hormuz, the Takaichi government has stated that Japan is insulated from direct impacts because only 6% of Japan’s total liquefied natural gas (LNG) imports pass through the Strait and that it holds three weeks of domestic LNG inventory.

However, this view overlooks several indirect risks if the Strait of Hormuz closure continues. First, Japan would be exposed to greater volatility in LNG spot prices, raising overall import costs. Second, higher fuels costs would translate into electricity price hikes at a time when Japanese households and businesses are already struggling with inflation. Third, government efforts to curtail these price increases would exacerbate Japan’s macroeconomic and fiscal pressures. The risks of fuel price volatility to domestic electricity prices and macroeconomic and fiscal stability were strikingly clear during the global energy crisis triggered by Russia’s invasion of Ukraine. Similar dynamics are beginning to play out as a result of the Iran conflict.

The severity of these risks depends on the duration of the Strait of Hormuz closure. In the medium to long term, Japan should prioritize deployment of domestic energy sources — particularly renewable energy — to hedge against volatile energy markets amid geopolitical uncertainty.

LNG price exposure cannot be mitigated through diversification

LNG accounts for over 30% of Japan’s power generation. A central pillar of the country’s LNG procurement strategy is portfolio diversification. Japanese utilities and trading houses source LNG from geographically diverse suppliers to reduce concentration risk and hedge against disruptions in any single production region. However, diversification does not shield Japan from price volatility resulting from severe global supply shocks.

This vulnerability became evident during the Russia-Ukraine war when Japan’s LNG import costs surged. In April 2021, LNG imports amounted to JPY221.3 billion. As Russia began to limit its pipeline gas exports to Europe, forcing European buyers to import more LNG and driving up global LNG prices, Japan’s monthly LNG import bill rose to nearly JPY600 billion. By August 2022, six months after the invasion, Japan paid over JPY878 billion for LNG imports in a single month — nearly a fourfold increase compared to April 2021 — despite Russian LNG accounting for only 8.7% of Japan’s total imports in 2021. Notably, Japan has not significantly reduced imports of Russian LNG since.

On an annual basis, and in United States (US) dollar terms, the total value of Japan’s LNG imports increased by 65% between 2021 and 2022, even as import volumes declined by 3%. In local currency terms, Japan’s LNG import bill increased by 98% over the same period due to the weakening yen. The country’s annual LNG spending remains above 2021 levels even though imports were 8.8 million tonnes lower in 2025 than four years prior, according to Kpler data. This underscores that diversification of supply sources does little to protect Japan from global LNG price hikes.

LNG spot prices for Japan followed a similar trend. From a low of USD5 per million British thermal units (MMBtu) in February 2021, rising European gas prices pushed Japan’s spot prices up to USD56/MMBtu in October 2021. Following the outbreak of the Russia-Ukraine war, spot prices spiked above USD70/MMBtu in 2022. Although Japan procures almost all of its LNG through long-term contracts, volatility in spot prices means Japanese buyers must bear the cost when they are forced to turn to the spot market.

Rising LNG costs have also prompted questions about whether Japan should deepen LNG procurement from the US to further diversify its supply. In 2025, Japanese companies signed 7.5 million tonnes per annum (MTPA) worth of new LNG contracts with US companies. These contracts are indexed to Henry Hub prices, which are expected to average USD5/MMBtu over the next five years, up from USD2.19/MMBtu in 2024. The US Energy Information Administration also forecasts an increase in average annual Henry Hub prices from USD3.53/MMBtu in 2025 to nearly USD4.40/MMBtu in 2027.

A similar dynamic is already emerging following the conflict in Iran that began in late February 2026. Since the closure of the Strait of Hormuz, the Japan-Korea Marker (JKM) — Asia’s benchmark LNG spot price — has doubled, reflecting tighter supply and intensifying  competition between Asia and Europe for available cargoes.

Although Japan’s LNG supply portfolio remains highly diversified and most long-term contracts are indexed to crude oil benchmarks, Japanese buyers remain materially exposed to supply disruptions in the Middle East.

Higher fuel costs lead to higher electricity prices

The rise in LNG prices and import costs directly translates to higher domestic electricity prices. Increased LNG costs in 2022 quickly passed through to Japan’s wholesale power markets and retail tariffs. On the Japan Electric Power Exchange (JEPX) wholesale market, the annual average system price rose from JPY13.43 per kilowatt-hour (kWh) in fiscal year (FY) 2021 to JPY20.41/kWh in FY2022, with temporary spikes exceeding JPY65/kWh during periods of extreme fuel price volatility. Retailers reliant on short-term procurement from the wholesale market faced sharp cost increases. By March 2023, 195 electricity retailers — about 27.6% of those registered by April 2021 — had suspended contracts, withdrawn, or exited the market, up from 31 a year earlier, a 6.3-fold increase.

Fuel price shocks also strained incumbent utilities. Nine of Japan’s ten major utilities reported net losses for the April–December 2022 period amid surging LNG procurement costs. Although electricity tariffs include a fuel cost adjustment mechanism, caps under regulated tariffs limited utilities’ ability to fully recover these costs during the price spike.

Household bills also increased sharply during this period. The Consumer Price Index (CPI) shows that household electricity charges rose 20% in 2022, reflecting the pass-through of higher fuel costs in Japan’s fuel-dependent power system. Tokyo Electric Power Company’s (TEPCO) average modelled monthly bill increased from JPY6,546 (USD36) in April 2021 to JPY9,126 (USD50) in late 2022, while Kansai Electric Power Company’s (KEPCO) rose from JPY6,499 (USD36.6) to JPY7,497 (USD41). As fuel costs climbed, seven utilities applied to revise regulated retail tariffs between late 2022 and early 2023, prompting regulators to reassess tariff assumptions based on updated fuel and wholesale market prices.

With fuel costs rising again amid the Iran conflict, TEPCO and Chubu Electric plan to accelerate the pass-through of higher procurement costs to retail tariffs from April 2026. Assuming crude oil prices of USD97 per barrel, annual household electricity costs are projected to increase by JPY15,000 (USD 95).

Price shocks will lead to further inflation and fiscal burden

Rising electricity and fuel costs weigh on consumption and economic growth, amplified by the depreciation of the yen — from JPY109.78/USD in 2021 to JPY131.37 in 2022, JPY140.5 in 2023, and exceeding JPY150 since 2024 — which directly increases the cost of imported energy.

Currency depreciation and rising fuel prices caused Japan’s total fossil fuel import bill to nearly double, from JPY17 trillion in 2021 to JPY33.7 trillion in 2022. This increase pushed the trade deficit to a record level of over JPY20 trillion (USD155 billion). Although prices have since moderated and LNG import volumes have declined, fossil fuel imports remained around JPY22 trillion in 2025, well above pre-2022 levels.

Japan’s CPI, which was negative in 2020 and 2021, rose to 2.5% in 2022 — exceeding the Bank of Japan’s (BOJ) 2% target for the first time in many years. It remained elevated at 3.2% in 2023 and 2025 as higher energy and import costs fed through to consumer prices.

Sustained Middle East tensions and a continued closure of the Strait of Hormuz would likely place additional upward pressure on prices. A USD10 increase in crude oil prices, for example, is estimated to raise inflation by 0.3–0.4 percentage points, underscoring Japan’s continued exposure to energy price shocks. Brent crude oil prices have already risen from USD72 per barrel on 27 February to USD103 on 17 March. Iran has warned that oil prices could reach as high as USD200 per barrel.

Unlike the US and the European Union (EU), which aggressively tightened monetary policy, the BOJ maintained negative rates and yield curve control through the 2022 energy crisis. Though policy normalization has begun — rates reached 0.75% in early 2026 — the BOJ remains cautious amid geopolitical uncertainty, leaving fiscal measures as the primary shock absorber.

Gross Domestic Product (GDP) growth has remained fragile, slowing to 0.9% in 2022 and just 0.1% in 2024. A 10% increase in oil prices could trim GDP by 0.1–0.3 percentage points in the near term. A prolonged shock in which fuel prices double could lead to a 3% GDP contraction in 2026, reversing the modest recovery underway.

These pressures constrain fiscal policy. Japan’s government debt is projected at 235% of GDP in 2025 — the highest among advanced economies — yet total energy subsidies amounted to JPY13.4 trillion between 2022 and 2025. A further JPY5 trillion (USD32 billion) support package approved immediately before the Iran conflict in February 2026 allocated JPY2.2 trillion to petrol price stabilization. In March 2026, as domestic gasoline prices rose to record levels, the Prime Minister announced subsidies to cap them at JPY170 per liter. While such measures may soften the impact of spiking crude oil prices, they also raise concerns about Japan’s long-term fiscal sustainability.

Domestic renewable energy is key to Japan’s energy security

Japanese policymakers have insisted that Japan is insulated from the most severe impacts from a closure of the Strait of Hormuz, citing the country’s limited physical exposure to LNG imports from the Middle East and the availability of domestic LNG inventories. Such claims may help reassure markets, but they may also understate the extent of the risks Japan faces.

A halt in Qatari LNG cargoes spells a 20% reduction in global LNG supply, reviving competition between Europe and Asia and putting upward pressure on prices. Japan’s total LNG import costs are likely to spike as they did in the wake of Russia’s invasion of Ukraine in 2022, even as its LNG import volumes declined. Higher LNG import costs are further compounded by the weakening of the Japanese yen. If the Strait of Hormuz remains closed,  escalating LNG prices could continue to raise domestic electricity rates for households and businesses well into 2026 and 2027. The government may attempt to ease the burden of high electricity prices through subsidies, but doing so would place additional strain on the country’s already fragile macroeconomic and fiscal position.

These risks underscore the limits of Japan’s LNG diversification strategy, which has not insulated the country from the global price shocks triggered by geopolitical disruptions. 

In the medium term, the Japanese government may attempt to strengthen energy security by accelerating nuclear reactor restarts. A recent Bloomberg New Energy Finance analysis suggests that restarting Japan’s largest nuclear reactor, Kashiwazaki-Kariwa Unit 6, could replace 10% of the LNG that was imported from the Persian Gulf in 2025. The restart was expected in January 2025 but has been delayed due to technical malfunctions. These delays illustrate the complex and protracted process of bringing the country’s nuclear fleet back online.

Japan’s energy security will be best served by scaling up domestic renewable energy generation. However, several factors currently constrain the rapid deployment of large-scale renewables. One challenge is that Japan’s largest utilities, including Tokyo Gas and JERA, have scaled back on their renewable energy commitments. Between 2021 and 2023, major utilities have added less than 2 gigawatts (GW) of renewable capacity, compared with more than 10GW of solar capacity installed during the period when generous feed-in tariffs were in place. 

Another, more fundamental, barrier for renewables is the persistent policy ambiguity that shapes these utilities’ investment strategies. Notably, Japan’s Green Transformation (GX) strategy places LNG, hydrogen, and ammonia co-firing on equal footing with renewables, limiting the incentives for renewable deployment. The 7th Strategic Energy Plan further reinforces this ambiguity by including a scenario in which renewables stagnate — implying greater reliance on LNG imports to close the supply gap.

Energy security is of paramount concern for Japanese policymakers. They can safeguard the country against global energy shocks by prioritizing renewables, providing clearer policy signals for utilities to make ambitious domestic renewable energy commitments, and introducing stronger incentives to support these investments.

• Awiqli^® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA¹
• Awiqli^® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these injections from seven to one per week¹
• The Awiqli^® approval reflects Novo Nordisk’s ongoing efforts to advance healthcare innovation and strengthen support for people living with diabetes

PLAINSBORO, N.J., March 26, 2026 /PRNewswire/ — Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli^® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycemic control (blood sugar) in adults living with type 2 diabetes.¹ This new approval offers the only once‑weekly basal insulin option, recognizing the importance of personalized care and the need for treatments that fit different patient routines and preferences for adults living with type 2 diabetes.^1,2

“Awiqli^® is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It’s helping to reframe what basal insulin care can look like,” said Anna Windle, PhD, Group Vice President, Clinical Development, Medical & Regulatory Affairs at Novo Nordisk Inc. “Awiqli^® may address challenges associated with the frequency of daily basal injections, by reducing them from seven to one per week. It is an important advancement for adults with type 2 diabetes who may benefit from an alternative treatment option.”

This approval is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli^® injection which comprises four randomized, active-controlled, treat-to-target trials in approximately 2,680 adults with uncontrolled type 2 diabetes, used in combination with a mealtime insulin or in combination with common oral anti-diabetic agents and/or GLP-1 receptor agonists. The clinical program evaluated once-weekly Awiqli^® vs. daily basal insulin and demonstrated efficacy in the primary endpoint of reduction of A1C across the ONWARDS pivotal clinical trial program for adults with type 2 diabetes. Across these ONWARDS trials, the safety profile of Awiqli^® was overall consistent with the daily basal insulin class.^3-6 Common adverse events include hypoglycemia (low blood sugar), serious allergic reactions (whole body reactions), reactions at the injection site, skin thickening or pits at the injection site (lipodystrophy), itching, rash, swelling of your hands and feet, and weight gain.¹

Please see below for Important Safety Information and please click here for the full Prescribing Information.

“The introduction of daily long-acting basal insulin injections more than 20 years ago, with the concept of “treat-to-target,” was a major contribution for adults with type 2 diabetes needing basal insulin therapy. However, some adults living with type 2 diabetes may still find it difficult to begin and stay on this type of daily basal insulin therapy. This underscores the need for new alternative insulin options that may help patients work with their health care providers to determine what treatment works best for them,” said Julio Rosenstock, MD, a Principal Investigator for the ONWARDS trial program and Clinical Professor of Medicine at the University of Texas Southwestern Medical Center. “Research supports weekly injectable diabetes medications can be associated with improved patient adherence. Having a weekly basal insulin option like insulin icodec-abae, may reshape insulin management in adults with type 2 diabetes, giving them a routine that feels more manageable as they work toward their blood sugar goals.”

Awiqli^® will be available nationwide in the US in the coming months. More information is available at www.awiqli.com.

About Awiqli^®
Awiqli^® (insulin icodec-abae) injection 700 units/mL is a prescription medicine and is the first and only FDA-approved once-weekly basal insulin indicated as an adjunct to diet and exercise for adults with type 2 diabetes.¹ Awiqli^® is designed as an alternative to daily basal insulin and its approval is supported by the ONWARDS clinical program, which evaluated its efficacy and safety across diverse adult populations living with type 2 diabetes.^3-6 Awiqli^® is administered once-weekly on the same day each week using the Awiqli^® FlexTouch^®.¹

Awiqli^® is approved in the US, EU, and 13 additional countries, with market-specific indications for diabetes.

What is Awiqli^® (insulin icodec-abae) injection 700 units/mL?

• Prescription Awiqli ^® is a long-acting insulin (U-700) that is used to control high blood sugar in adults with type 2 diabetes mellitus
• It is not known if Awiqli^® is safe and effective in children and adolescents
• Awiqli^® is available in 1 concentration: U-700 

Important Safety Information
Do not share your Awiqli^® FlexTouch^® pen or needles with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.

Make sure you use the right type and dose of insulin. Always check the label on your insulin pen before each injection to avoid mix-ups with Awiqli^® and other insulin products or injectable medicines used to treat diabetes. If you use another injectable medicine to treat your diabetes, pay close attention to how you select your Awiqli^® dosage. The dosage of Awiqli^® is different from other injectable medicines used to treat diabetes.

Always make sure that you select the correct dosage of your Awiqli^® FlexTouch^® pen as prescribed by your healthcare provider, to avoid dosing errors and accidental overdose. People who are blind or have vision problems should not use this pen without help from a person trained to use the pen.

Do not dial the maximum single dosage (700 units) of your Awiqli^® FlexTouch^® pen, unless prescribed by your healthcare provider.

Do not use a syringe to withdraw Awiqli^® from your pen.

Talk to your healthcare provider if you have any questions about how to correctly dose Awiqli^® FlexTouch^®. 

Who should not take Awiqli^®?
Do not take Awiqli^® if you:

• are having an episode of low blood sugar (hypoglycemia)
• have an allergy to Awiqli^® or any of the ingredients in Awiqli^®. See the full Patient Information for a complete listing of ingredients in Awiqli^®

Before taking Awiqli^®, tell your healthcare provider about all your medical conditions, including if you are:

• have liver or kidney problems
• take other medicines, especially ones called TZDs (thiazolidinediones)
• have heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with Awiqli^®
• pregnant, planning to become pregnant, or are breastfeeding
• taking new prescription or over-the-counter medicines, vitamins, or herbal supplements

Talk to your health care provider about low blood sugar and how to manage it.

How should I take Awiqli^® FlexTouch^®?

• Read the Instructions for Use that come with your Awiqli^® FlexTouch^® pen
• Your healthcare provider should show you how to use Awiqli^® FlexTouch^® pen before you use it for the first time
• Take Awiqli^® exactly as your healthcare provider tells you to. Do not do any conversion of your dose. The dose counter always shows the selected dose in units. Awiqli^® FlexTouch^® pens are made to deliver your insulin dose in units
• Know the type and strength of insulin you take. Do not change the type of insulin you take unless your health care provider tells you to. The amount of insulin and best time for you to take your insulin may need to change if you take different types of insulin
• Inject Awiqli^® FlexTouch^® 1 time each week on any day of the week on the same day each week
• If you need to change the day of the week, you may do so if your last dose has been at least 4 days
• If you have missed your dose, take your missed dose as soon as possible as long as it has been 4 days or less. Then continue the 1 time each week schedule 1 week from the day your missed dose was taken
• If more than 4 days has passed, skip the missed dose and take your next Awiqli^® dose on your regularly scheduled day.
• Check your blood sugar levels. Ask your health care provider what your blood sugar levels should be and when you should check them
• Never inject Awiqli^® FlexTouch^® into a vein or muscle or use Awiqli^® in an infusion pump
• Never use a syringe to remove Awiqli^® from the FlexTouch^® pen
• Do not dilute or mix Awiqli^® with any other insulin or solution
• Awiqli^® FlexTouch^® can be injected under the skin (subcutaneously) of your upper legs (thighs), upper arms, or stomach area (abdomen)
• Change (rotate) your injection sites within the area you choose with each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.
  • Do not use the exact same spot for each injection
  • Do not inject where the skin has pits, is thickened, or has lumps
  • Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin
• Keep Awiqli and all medicines out of the reach of children.

What should I avoid while taking Awiqli^®?

• Do not drive or operate heavy machinery, until you know how Awiqli^® affects you
• Do not drink alcohol or use prescription or over-the-counter medicines that contain alcohol

What are the possible side effects of Awiqli^®?

Awiqli^® may cause serious side effects that can be life-threatening, including:

• Low blood sugar (hypoglycemia). Signs and symptoms that may indicate low blood sugar include: dizziness or light-headedness, sweating, confusion, fast heartbeat, blurred vision, slurred speech, shakiness, anxiety, irritability, mood changes, hunger and headache
• Severe allergic reactions (whole body reaction). Stop using Awiqli and get medical help right away, if you have any of these signs or symptoms of a severe allergic reaction: a rash over you whole body, trouble breathing, a fast heartbeat or sweating
• Low potassium in your blood (hypokalemia)
• Heart failure in some people if taken with thiazolidinediones (TZDs). This can happen even if you have never had heart failure or heart problems. If you already have heart failure, it may get worse while you take TZDs with Awiqli^®. Tell your health care provider if you have any new or worse symptoms of heart failure including shortness of breath, tiredness, swelling of your ankles or feet, and sudden weight gain

Your insulin dose may need to change because of change in level of physical activity or exercise, increased stress, change in diet, weight gain or loss, or illness

Common side effects may include: hypoglycemia, serious allergic reactions (whole body reactions), reactions at the injection site, skin thickening or pits at the injection site (lipodystrophy), itching, rash, swelling of your hands and feet, and weight gain

Get emergency medical help if you have trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion

These are not all the possible side effects of Awiqli^®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088

Please click here for the full Prescribing Information.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company that’s been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs approximately 10,000 people throughout the country across more than 10 manufacturing, R&D and corporate locations in seven states plus Washington DC. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.

References:

1. Awiqli® (insulin icodec-abae) [package insert]. Plainsboro, NJ: Novo Nordisk Inc.
2. American Diabetes Association Professional Practice Committee for Diabetes*; Facilitating positive health behaviors and well-being to improve health outcomes: Standards of care in diabetes—2026. Diabetes Care 1 January 2026; 49(suppl 1-5):S89–S131. https://doi.org/10.2337/dc26-S005
3. Rosenstock J, Gowda A, Liang B. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med. 2023 2023;389(16):1533. doi:10.1056/NEJMc2310221
4. Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023 https://doi.org/10.1016/S2213-8587(23)00093-1
5. Lingvay I, Asong M, Desouza C, et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial. JAMA. 2023;330(3):228–237. doi:10.1001/jama.2023.11313
6. Mathieu C, Ásbjörnsdóttir B, Bajaj H, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. 2023 https://doi.org/10.1016/S0140-6736(23)00520-

Awiqli^® is a registered trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2026 Novo Nordisk All rights reserved. US26AWQ00001 March 2026

SOURCE Novo Nordisk